Phase 1/2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of a Single Intravenous Infusion of NBIB-0000223 in Patients With Friedreich's Ataxia

Key Inclusion Criteria: * Has both a clinical and genetic diagnosis of Friedreich's Ataxia, with diagnosis occurring at least 1 year prior to Screening and when the participant was age ≤16 years. * Documented prior genetic diagnosis of Friedreich's Ataxia with a pathogenic GAA trinucleotide repeat expansion in intron 1 of both frataxin alleles, based on analysis by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. * Clinical evidence of symptomatic neurologic disease consistent with Friedreich's Ataxia. * Have an Modified Friedreich Ataxia Rating Scale (mFARS) o…